BARDA Director Gary Disbrow (Graeme Jennings/Pool via AP Images)
June 28, 2024 01:50 PM EDTUpdated 03:38 PM
Pharma
Coronavirus

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

Max Bayer

Pharma Reporter

In 2023, Vaxart halt­ed work on its oral vac­cine for Covid-19, and didn’t even have enough mon­ey to fin­ish 2024.

Now, the US gov­ern­ment is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times